The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Nimotuzumab combined with radiotherapy on esophageal cancer: Preliminary study of a phase II clinical trial.
Jun Liang
No relevant relationships to disclose
Luhua Wang
No relevant relationships to disclose
Mingyan E
No relevant relationships to disclose
Wu Gang
No relevant relationships to disclose
Lujun Zhao
No relevant relationships to disclose
Xia Li
No relevant relationships to disclose
Xia Xiu
No relevant relationships to disclose
Ning Li
No relevant relationships to disclose
Bo Chen
No relevant relationships to disclose
Zhouguang Hui
No relevant relationships to disclose
Jima Lv
No relevant relationships to disclose
Hui Fang
No relevant relationships to disclose
Yu Tang
No relevant relationships to disclose
Nan Bi
No relevant relationships to disclose
Wenqing Wang
No relevant relationships to disclose
Yirui Zhai
No relevant relationships to disclose
Tao Li
No relevant relationships to disclose
Dongfu Chen
No relevant relationships to disclose
Shuangmei Zou
No relevant relationships to disclose
Ning Lu
No relevant relationships to disclose